Subject index: Volume 11 (1997)

• Book ID: 104323298
• Publisher: Elsevier Science
• Year: 1997
• Tongue: English
• Weight: 602 KB
• Volume: 11
• Category: Article
• ISSN: 0268-960X
• DOI: 10.1016/s0268-960x(97)90023-0

✦ Synopsis

Anthrapyrazoles, 207 Antibody/antibodies to IFN-[alpha] in myeloma patients, 193 monoclonal, see Monoclonal antibodies Antibody-directed enzyme prodrug therapy systems for daunorubicin, 2 15 Antiphospholipid syndrome, 72-3 therapy, 76-7 Antiplatelet agents, new, 178-90 Antiproliferative effect of IFN-[alpha] in myeloma, 192 Antithrombin III deficiency, 74 Apoptosis and anthracyclines, 203-4 Ara-C, see Cytosine arabinoside Arrhythmias, anthracycline-associated, 2 12 Arthropathy, HTLV-I-associated, 97 ASCO guidelines on haemopoietic growth factor use, 16-27 Asparaginase and Ara-C acute myeloid leukaemia, 41 Aspirin, 179-80 antiphospholipid syndrome, 76 dipyridamole combined with, trials of, 182 ticlopidine combined with, trials of, 183 Australian Leukaemia Study Group myeloma II trial of IFN-[alpha], 195, 197 Autoantibodies to IFN-[alpha] in myeloma patients, 193 Autoimmunity in chronic lymphocytic leukaemia, 124 in tropical spastic paraparesis pathogenesis, 99 Autologous blood or marrow transplantation in acute myelogenous leukaemia, see Myeloid leukaemia, acute in chronic myeloid leukaemia, 154-9 haemopoietic growth factors following, 19-20 high-dose Ara-C compared with, in acute myeloid leukaemia,42-3 Eastern Co-operative Oncology Group guidelines on haemopoietic growth factor use, 16-27 trial of IFN-[alpha] in multiple myeloma, 193, 195 ECOG, see Eastern Co-operative Oncology Group Enzymes, cellular, anthracycline interactions, 202-3, see also Antibody-directed enzyme prodrug therapy systems Eosinophil(s), morphological abnormalities, 133 Eosinophilia